DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
5 Undervalued S&P 500 Stocks to Buy for 2024
by Sweta Killa
Investors seeking to tap the bullish momentum in the S&P 500 should invest in undervalued stocks like Everest Group (EG), Comcast (CMCSA), 3M Company (MMM), Molson Coors (TAP) and DaVita (DVA).
5 Top Growth Stocks to Make the Most of Santa Claus Rally
by Nalak Das
We have narrowed our search to five growth stocks that have solid upside left for the rest of 2023. These are: DOCU, DUOL, DVA, VRT, PLTR.
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Masimo's (MASI) ORi Favored by Study for PaO2 Information
by Zacks Equity Research
Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Best Growth Stocks to Buy for December 12th
by Zacks Equity Research
GFF, DVA and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 12, 2023.
The Zacks Analyst Blog Highlights Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita
by Zacks Equity Research
Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita are part of the Zacks top Analyst Blog.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 Undervalued Stocks in the S&P 500 ETF to Buy for 2024
by Sweta Killa
Many stocks in the S&P 500 ETF may be undervalued and have the potential to rise toward their peak values.
Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.
BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod
by Zacks Equity Research
BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.
Cooper Companies (COO) Q4 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) fourth-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid moderating expenses.
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
by Zacks Equity Research
AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
by Zacks Equity Research
Centene's (CNC) Health Insurance Marketplace brand Ambetter strengthens its provider network with Broward Health.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene (CNC), Mindoula to Address Mental Health Issues in Indiana
by Zacks Equity Research
Centene's (CNC) unit, MHS, collaborates with Mindoula to enhance mental health support for Hoosiers and attract more customers to opt for CNC's Medicaid plans.
DaVita HealthCare (DVA) Up 22.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.
Top 5 Mid-Cap Stocks Likely to Turn Large-Cap in 2024
by Nalak Das
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, XPO, AIZ, EME, DUOL.
Best Growth Stocks to Buy for December 7th
by Zacks Equity Research
EGHT, DVA and BBSI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 7, 2023.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.